Zhonghe Gene Unveils China's First Automated Kb-Scale Gene Assembly Instrument AutoSp1500

DNA synthesis technology is one of the core technologies in synthetic biology, and breakthroughs in this field have significantly driven the development of the entire synthetic biology industry.

The first domestic automated “Kb-level Gene Splicer” (AutoSp1500), independently developed by Tianjin ZHONGHE GENE Technology Co., Ltd. (ZHONGHE GENE), has completed testing and officially released its working prototype. This device adopts an innovative splicing process and the world’s first open-source service model, enabling fully automated gene splicing at lower costs and in shorter cycles.

This device adopts an innovative DNA assembly process and the world’s first open-source DNA assembly service model. It not only fills the domestic gap in foundational synthetic biology equipment for gene assembly and error correction, but also addresses the limitations of foreign automated assembly systems in their application models within China, thereby supporting the healthy development of China’s synthetic biology sector.

On Tuesday, September 26 at 19:30, the 30th session of VCBeat Select New Product Appreciation invitesCEO of ZHONGHE GENELu Xiaoyun、Tian Zhenyang, COO of ZHONGHE GENE, presenting China’s first automated Kb-level gene splicing instrument.

Compared with traditional processes, it enables unattended, fully automated control, reduces consumable costs by 50%, and shortens the gene synthesis turnaround time for end users from two weeks to less than one week.

It is the world’s only open-source gene assembler, adopting an open-source assembly service model, equipped with localized gene segmentation software, and utilizing an open-source short-chain DNA material input mode. This approach fully ensures customers’ flexibility, confidentiality, and cost-effectiveness in gene synthesis, making it suitable for R&D and industrial applications in various fields such as biopharmaceuticals, biomanufacturing, DNA storage, and synthetic biology.

Scan the QR code on the poster to add our assistant and reserve your spot for the live stream.

Lu Xiaoyun

CEO of ZHONGHE GENE

Ph.D. from Northwestern Polytechnical University; formerly an Assistant Researcher at the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences; recipient of the National Natural Science Foundation for Young Scholars; listed among the Tianjin U30 in the 2022 “Science and Technology Innovation China” Youth Entrepreneurship List.

Published more than 10 papers in journals such as Nature Communications and ACS Catalysis; filed a total of 16 international and domestic patents, including multiple original patents on DNA biosynthesis, with 4 granted. Focuses on DNA synthesis and applications, with in-depth understanding and unique insights into this field.

Tian Zhenyang

COO, ZHONGHE GENE

Ph.D. from Nankai University; Postdoctoral Fellow at the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences. Previously served as Manager of the New Technology R&D Department at a National-Local Joint Innovation Center for Modern Traditional Chinese Medicine. Conducted in-depth research in gene chips, gene sequencing, and DNA biosynthesis. Recipient of the National Natural Science Foundation of China for Young Scholars; participated in projects funded by the National Natural Science Foundation of China and the National High-Tech Research and Development Program (863 Program). Authored four academic papers and holds two granted patents out of four invention patent applications.

Tianjin ZHONGHE GENE Technology Co., Ltd. (ZHONGHE GENE) is the first enterprise in China to focus on the development, production, and sales of related equipment, with third-generation enzymatic gene synthesis technology as its core.

The company’s core technology, “Two-Step Cyclic Enzymatic DNA Synthesis Technology,” originates from the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, and holds a leading international position in the field of DNA biosynthesis. Building on this foundation, the company has successfully developed a proof-of-concept prototype of the first-generation Oligo biosynthesizer and a working prototype of a gene bio-assembly instrument. The related technologies have obtained multiple intellectual property certifications and accepted applications, and have been honored with awards including the “Gold Award at the Annual Synthetic Biology Innovation Competition,” First Prize in the Tianjin Division of the China Innovation and Entrepreneurship Competition, Excellence Award in the National Finals, and Second Prize at the “Taihu Cup” International Elite Innovation and Entrepreneurship Competition.

With the vision of “Synthesizing Genes, Transforming the World,” the company has developed a desktop all-in-one kilobase (Kb)-scale gene synthesizer, pioneering new market application models. Its products are widely used in medical diagnostics, drug development, and basic scientific research services. The company is committed to becoming a pioneer in core foundational equipment for synthetic biology and a globally leading supplier of long-chain gene biosynthesis instruments.

“Artery Select New Product Launch” is a live-streaming program under “Artery Select” that supports medical companies in launching their innovative products. The program’s mission is to empower every milestone launch of medical innovation products.

Scan the QR code below to contact the assistant and reserve a spot for the live stream.

(If already added, please proactively contact the assistant.)